Epigenetic research reveals a potential treatment for CRC and other solid tumors

Johns Hopkins, Howard University reform collaboration to advance health equity

A collaborative effort to eliminate cancer health disparities among African Americans and other underserved populations in the Washington, DC, area is being reignited at the Johns Hopkins Kimmel Cancer Center and the Howard University Cancer Center.

January 10, 2025

Vol.51 No.01

In Brief

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

Stephen BaylinAndrew FeinbergJohns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center researchers Stephen Baylin and Andrew Feinberg were awarded the 2022–2023 Harvey Prize in the field of Science and Technology by the Technion—Israel Institute of Technology.

December 13, 2024

Vol.50 No.46

Clinical Roundup

CAR T cells armed with IL-15 show promise in treating solid cancers

A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.

December 06, 2024

Vol.50 No.45

Clinical Roundup

VHIO’s novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

One-third of HER2-positive tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d’Hebron Institute of Oncology’s Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute, Barcelona, have developed novel chimeric antigen receptor T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Scientists identify genes that help cancer cells survive in the bloodstream

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they’ve escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop cancer recurrence, and one—MUC1—is already in clinical trials. The research was published online Sept. 28 in...

November 08, 2024

Vol.50 No.42

Clinical Roundup

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.

October 25, 2024

Vol.50 No.40

Epigenetic research reveals a potential treatment for CRC and other solid tumors

YOU MAY BE INTERESTED IN

Johns Hopkins, Howard University reform collaboration to advance health equity

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

CAR T cells armed with IL-15 show promise in treating solid cancers

VHIO’s novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2-positive solid tumors

Scientists identify genes that help cancer cells survive in the bloodstream

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Renew today!

Subscriber content

Never miss an issue!

Login